How to Write a Pharma Media Investment Thesis
A one-page structure for a pharma media investment thesis that links evidence, assumptions, downside risk, and the decision you are asking leadership to make.
The short answer
A media investment thesis is a one-page argument for why a specific amount of money should go to a specific plan, what has to be true for that to be a good decision, and how you will know early if it is not. It is shorter than a media plan and more honest than a pitch deck. Its job is to get a decision, not to impress.
Directors who can write a clear thesis tend to get budgets approved faster, because finance and brand leadership can see the logic and the risk in one place.
The one-page structure
Use six short sections. If one runs longer than a paragraph, it is probably doing work that belongs in an appendix.
- The ask. The amount, the period, and what it funds. "Approve $2.5 million for HCP video in the first half, released in two tranches."
- The problem. The commercial problem media is meant to address, in the brand's language, not media language.
- The mechanism. How media is expected to change behavior. Be specific about audience, message job, and channel role.
- The evidence. What you already know, labeled by strength. Separate measured results from benchmarks and from assumptions.
- The key assumptions. The two or three things that must be true. Say what happens if each is wrong.
- The checkpoints. What you will look at, when, and what decision each checkpoint triggers.
Label evidence by strength
The most common weakness in investment arguments is mixing strong and weak evidence without saying so. A simple three-tier label helps.
| Tier | Example | How to use it |
|---|---|---|
| Measured causal | A holdout test showed an incremental lift with a stated interval | Can support scale decisions |
| Measured associative | An attributed Rx report or engagement data | Supports direction, not size of effect |
| External or assumed | Industry benchmark, partner claim, analogue brand | Supports planning ranges only |
If most of your thesis rests on the bottom tier, say so. That is a reason to structure the investment in tranches, not a reason to hide it. The distinction between attributed and incremental prescriptions is usually the most important one to get right.
Make the downside explicit
Leadership approves risk more readily when they can see its size. For each key assumption, state the downside in plain numbers: "If target-list match rates come in at 40% instead of 60%, effective reach drops by a third and we would pause the second tranche." This also protects you later. A decision made with a clearly stated risk is easier to defend than one made on an optimistic plan.
Tie checkpoints to real decisions
A checkpoint that does not lead to a decision is a status meeting. Good checkpoints look like this:
- Week 4: Target-list reach above an agreed threshold, otherwise shift spend to the stronger partner.
- Week 10: Quality metrics within range, otherwise pause and investigate supply.
- Post-campaign: Outcome study result reviewed against the pre-agreed threshold for renewal.
See the scenario planning guide for how to set trigger-based reallocations.
What to leave out
Leave out channel descriptions leadership already understands, lists of every tactic, and optimistic projections without ranges. If you include a forecast, show a range and name its inputs. The guide to forecasting incremental prescriptions covers how to do that without false precision.
Hypothetical example
"We ask for $1.8 million for DTC CTV in Q1 and Q2, released as $1.0 million in Q1 and $0.8 million in Q2. The brand's problem is low consideration among diagnosed adults who are not currently treated. CTV is expected to add reach among this group at a lower cost per reached household than current video. Evidence: associative data from last year's online video suggests site visits rise in exposed households, but we have no causal estimate. Key assumption: household targeting reaches the intended audience at an acceptable rate. Checkpoint: a geo-based test read at the end of Q1 determines whether the Q2 tranche is released." All figures are illustrative.
Practical takeaway
Draft the thesis before the media plan. If you cannot fill all six sections in one page, the plan is not ready for approval, and the gap you found is the most useful thing the exercise produced.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.